About the Company
Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable T cells to eliminate tumors.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ADXS News
Advaxis Inc (FAD.SG)
Check a company’s competitiveness in the job market with alternative data that tracks hiring, job openings, and more.
Advaxis Cancer Immunotherapy on Hold Due to Patient Death
The FDA placed a halt on clinical trials involving a cancer immunotherapy from Advaxis because of concerns a bacteria used to deliver the drug contributed to a patient death. The FDA placed a halt ...
Ayala Pharmaceuticals (ADXS) Earnings Dates & Reports
View upcoming earnings forecasts and in-depth analysis of company forecasts.
Ayala Pharmaceuticals Inc (ADXS)
Investing.com – U.S. stocks were lower after the close on Tuesday, as losses in the Consumer Services, Basic Materials and Industrials sectors led shares lower. At the close in... Investing.com ...
Anal Cancer Market Size, Share, Growth 2031
Competitive Players The key global anal cancer market players are Advaxis, Inc., Eli Lilly and Company, Merck KGaA, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Amgen Inc., Atara ...
AstraZeneca and Kyowa Hakko Kirin partner on immuno-oncology
INCB24360 and MEDI4736 with Advaxis' immunotherapy vaccine, ADXS-HPV. Market analysts Decision Resources forecast that the immunotherapy market will grow from just over $1 billion in 2012 to ...
Pitching a Column to Inc.com
Inc. welcomes column proposals from experts and thought leaders at the top of their industries. Your proposal should include: Why you will make an excellent contributor to Inc.com Topics of ...
Ayala Pharmaceuticals files Form 15 to voluntarily deregister and suspend reporting obligations
Ayala Pharmaceuticals (OTCQX:ADXS) on Thursday announced that it filed a Form 15 with the SEC to deregister its common stock and to suspend its reporting obligations. Source: Press Release ...
About Inc.com | Everything You Need to Know to Grow and Start Your Business
Inc. is the voice of the American entrepreneur. We inspire, inform, and document the most fascinating people in business: the risk-takers, the innovators, and the ultra-driven go-getters that ...
Alphabet Inc. Cl C
1 Day GOOG 1.06% DJIA 0.34% S&P 500 0.12% Technology -0.96% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum ...
Alphabet Inc. Cl A
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Loading the latest forecasts...